Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid (hexenoyl) moiety covalently attached at the N-terminus. This structural modification confers resistance to cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly degrades native GHRH in plasma, thereby substantially extending the peptide's effective circulating half-life.

The peptide binds selectively to the GHRH receptor (GRF receptor), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland. Receptor engagement activates the Gs-protein/adenylate cyclase/cyclic AMP signaling cascade, stimulating both synthesis and pulsatile secretion of endogenous growth hormone (GH). This mechanism preserves the physiological pulsatile GH release pattern and maintains hypothalamic-pituitary negative-feedback regulation, in contrast to exogenous recombinant GH administration.

Released GH acts on adipocytes to promote lipolysis, with preferential effect on visceral adipose tissue relative to subcutaneous fat. GH also stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which mediates downstream anabolic effects including modest increases in lean body mass. The net metabolic result is a selective reduction in visceral adiposity accompanied by improvements in body composition.

Tesamorelin received FDA approval in November 2010 as Egrifta for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, based on two pivotal Phase III randomized, double-blind, placebo-controlled trials. In LIPO-010 (n=412), tesamorelin reduced visceral adipose tissue (VAT) by a mean of 27.8 cm² versus a 5.1 cm² increase with placebo at 26 weeks (P less than 0.001; relative difference -19.6%). In CTR-1011 (n=404), VAT declined by 21 cm² versus 1 cm² with placebo (P less than 0.001; relative difference -11.7%). Pooled analyses reported a net 15.4% reduction in VAT relative to placebo. IGF-1 rose by approximately 107-109 ng/mL, lean body mass increased by 1.3 kg versus a 0.2 kg decline with placebo, and waist circumference fell by 2-3 cm. Extension phases to 52 weeks confirmed maintained benefit on continuous therapy; VAT returned toward baseline after discontinuation.

A 2026 meta-analysis of five RCTs confirmed pooled VAT reduction of -27.71 cm² (95% CI -38.37 to -17.06; P less than 0.001) and trunk fat reduction of -1.18 kg (95% CI -1.40 to -0.96).

In a 61-participant multicenter randomized trial published in Lancet HIV (Stanley et al., 2019), tesamorelin 2 mg/day for 12 months reduced hepatic fat fraction by an absolute 4.1 percentage points (P=0.02; -37% relative reduction) and reduced fibrosis progression in HIV-associated nonalcoholic fatty liver disease (10.5% progression vs 37.5% with placebo; P=0.04).

A 152-person randomized controlled trial in healthy older adults and those with amnestic mild cognitive impairment (Baker et al., published in PMC3764914) found that tesamorelin 1 mg/day for 20 weeks significantly improved executive function on a four-test battery (P=0.005) with a trend toward improved verbal memory (P=0.08); effects were not sustained at 10-week washout.

Typical dosage: 2 mg (daily).

The FDA-approved dosage for Egrifta SV is 1.4 mg (0.35 mL of reconstituted solution) subcutaneously once daily, injected into the abdomen with rotation of injection sites; this reflects the current commercial formulation as of the 2025 prescribing information.

The dose used in both pivotal Phase III HIV lipodystrophy trials and the subsequent NAFLD randomized trial was 2 mg subcutaneously once daily. The cognitive function trial by Baker et al. used 1 mg subcutaneously once daily, administered approximately 30 minutes before bedtime, for 20 weeks.

Trial durations ranged from 20 weeks (cognitive function study) to 12 months (NAFLD and integrase-inhibitor studies). Extension-phase data from the pivotal trials demonstrate that VAT reductions reverse toward baseline within weeks of stopping therapy, indicating that continuous administration is necessary to maintain efficacy; this has meaningful implications for long-term cost and monitoring burden.

Off-label use in non-HIV individuals in wellness and longevity clinic settings is reported at 1-2 mg subcutaneously once daily, sometimes in 8- to 12-week cycles. No published dose-ranging or pharmacokinetic studies exist for non-HIV populations. The FDA prescribing information recommends assessment of IGF-1 levels and fasting glucose or HbA1c at baseline and periodically throughout treatment.

This content is provided for educational and research reference purposes only and does not constitute medical advice. Tesamorelin is a prescription medication in the United States; its use requires physician oversight, appropriate patient selection, and ongoing laboratory monitoring.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No peer-reviewed controlled trials have evaluated tesamorelin in combination with other peptides for performance, body composition, or anti-aging purposes in otherwise healthy individuals.

In anecdotal community use and off-label wellness clinic practice, tesamorelin is frequently paired with growth hormone-releasing peptides (GHRPs) such as ipamorelin or GHRP-6. The pharmacological rationale is that GHRH analogs acting on the GRF receptor and GHRPs acting on the ghrelin receptor (GHS-R1a) stimulate pulsatile GH secretion via complementary pathways; basic pharmacology studies suggest concurrent activation of both receptor types amplifies GH output more than either alone. CJC-1295, a GHRH analog with longer half-life, is sometimes added or substituted in reported anecdotal protocols. Some clinicians also combine tesamorelin with sermorelin.

All such combination protocols are anecdotal, carry an additive risk of supraphysiological IGF-1 elevation, lack published safety or efficacy data, and cannot be recommended on the basis of available evidence.

Tesamorelin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Joint pain, peripheral edema

The most common adverse events in the Phase III trials were injection site reactions (erythema, pruritus, pain), occurring in approximately 25% of tesamorelin-treated patients versus 14% on placebo. Systemic reactions included peripheral edema (6.1% vs 2.3%), arthralgia, myalgia (3.7-10.8% vs 0-1.6%), and extremity pain. Hypersensitivity reactions occurred in approximately 4% of patients and ranged from rash, urticaria, and flushing to rare anaphylaxis.

Glucose intolerance is a clinically significant safety concern. Pooled Phase III data showed 5% of tesamorelin-treated patients developed HbA1c greater than or equal to 6.5% versus 1% of placebo controls, corresponding to a hazard ratio of approximately 3.3 for new-onset diabetes mellitus. Fasting glucose and glycated hemoglobin should be assessed before initiating therapy and monitored periodically.

Elevated IGF-1 was observed in 47% of treated patients exceeding 2 standard deviation scores above the age- and sex-adjusted mean; 36% exceeded 3 SDS. While no increased malignancy incidence was observed in clinical trials, the FDA label identifies theoretical neoplasm risk from supraphysiological IGF-1 and requires periodic monitoring with consideration of discontinuation if levels persistently exceed 3 SDS above the age-adjusted mean.

Absolute contraindications include active malignancy, disruption of the hypothalamic-pituitary axis (prior irradiation or hypophysectomy), known hypersensitivity to tesamorelin or mannitol, and pregnancy (FDA Pregnancy Category X, with demonstrated embryotoxicity in preclinical studies). Fluid retention may precipitate or worsen carpal tunnel syndrome. Long-term safety data beyond 52 weeks remain limited.